Drug General Information (ID: DDIZNA0X4Y)
Drug Name			Insulin detemir		Drug Info		Linagliptin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antidiabetic Agents				Dpp4 Inhibitors/Antidiabetic Agents
Structure

Mechanism of Insulin detemir-Linagliptin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Insulin detemir				Linagliptin
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Insulin detemir and Linagliptin

Recommended Action
Management		A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.

References
1	Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
2	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
3	Product Information. Januvia (sitagliptin). Merck &amp Company Inc, West Point, PA.